Project 1: Adjuvanted Protein Vaccines for Pandemic Preparedness

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: Li  Liang
Organization: UNIVERSITY OF CALIFORNIA-IRVINE
Fiscal Year: 2024
Award: $7,511,446
Funding agency: National Institute of Allergy and Infectious Diseases

Project Summary/Abstract - Project 1: Adjuvanted Protein Vaccines for Pandemic Preparedness
In preparation for possible future pandemics, our goals for Project 1 are to characterize immune responses and
to develop new adjuvanted multivalent recombinant protein vaccines that are cross-protective within these
target priority virus families with pandemic risk. We will interact closely with other Projects/Cores in the UCI
ReVAMPP program. Each year we will supply Projects 3-5 and Translational Immunology Core with lead
protein vaccine formulations for rodent and non-human primate immunity and challenge models and
transitional human studies, as well as provide a protein microarray for antibody profiling in serum samples from
all projects in the ReVAMPP programs. We will also support Project 2 on formulation and characterization of
mRNA LNP candidates with various lipids, and collaborate with the Regulatory Science Core to ensure the
work performed in this project meets the standards of a quality system allowing the rapid transfer of the
recombinant protein vaccine technologies for their production and further IND-enabling studies. We propose
five Specific Aims: (1) Adjuvant formulation and characterization for recombinant protein vaccines against
Bunyaviruses, Paramyxoviruses and Picornaviruses (2) Immunoprofiling of multivalent recombinant protein
vaccine formulations in rodents via i.m.; (3) To develop the process for the production of six recombinant
protein vaccine antigen candidates against Bunyavirales, Paramyxoviridae, and Picornaviridae. (4) Protein
vaccines for systemic and mucosal immunity. (5) Breadth/durability of multivalent protein vaccine formulations.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Adjuvant><Agonist><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody Response><Antigens><Assay><Bioassay><Biochemical><Biological><Biological Assay><Biophysics><Blood Serum><Body Tissues><Bunyavirales><Bunyavirus><COVID-19 virus><COVID19 virus><Characteristics><Chlamydia><CoV-2><CoV2><Collaborations><Coxiella><Cyclic GMP><Documentation><Dose><Encapsulated><Ensure><Evaluation><Family><Family Picornaviridae><Fermentation><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Formulation><Funding><Goals><Grippe><Guanosine Cyclic Monophosphate><Human><Hydrogen Oxide><Immune response><Immunity><Immunization><Immunological response><Influenza><Intramuscular><Lead><Lipids><Manufacturer><Messenger RNA><Mice><Mice Mammals><Microfluidics><Miyagawanella><Modeling><Modern Man><Mucosal Immunity><Murine><Mus><NIAID><National Institute of Allergy and Infectious Disease><Oils><Orthobunyavirus><Paramyxoviridae><Paramyxovirus><Pb element><Picornaviridae><Picornaviruses><Preparation><Process><Production><Protein Biochips><Protein Chips><Protein Microarray><Protein Microchips><Proteins><RNA vaccine><RNA-based vaccine><Recombinant Proteins><Recombinants><Reducing Agents><Reductants><Reproducibility><Rodent><Rodentia><Rodents Mammals><Route><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Science><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Spleen><Spleen Reticuloendothelial System><Squalene><System><T cell response><T-Cells><T-Lymphocyte><Technology><Technology Transfer><Testing><Time><Tissues><Vaccine Antigen><Vaccine Research><Vaccines><Virus><Virus-like particle><Water><Work><Wuhan coronavirus><bedsonia><biodefense><biologic><biophysical foundation><biophysical principles><biophysical sciences><cGMP><commercial scale manufacturing><coronavirus disease 2019 virus><coronavirus disease-19 virus><cost><design><designing><develop a vaccine><develop vaccines><development of a vaccine><flow cytophotometry><future pandemic><hCoV19><heavy metal Pb><heavy metal lead><host response><immune response to vaccination><immune response to vaccines><immune system response><immunogen><immunogenicity><immunoresponse><lead candidate><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA vaccine><mRNA-based vaccine><manufacturing ramp-up><manufacturing scale-up><microbial><model of animal><nCoV2><nano emulsion><nano particle><nano-sized particle><nanoemulsion><nanoparticle><nanosized particle><next pandemic><non-human primate><nonhuman primate><novel><pandemic concern><pandemic disease preparedness><pandemic planning><pandemic potential><pandemic preparedness><pandemic readiness><pandemic risk><pandemic threat><pathogen><preparations><process evaluation><programs><response><scale up batch><scale up production><thymus derived lymphocyte><translational immunology><upscale manufacturing><vaccine associated immune response><vaccine candidate><vaccine development><vaccine formulation><vaccine immune response><vaccine immunogenicity><vaccine induced immune response><vaccine-related research><virus-like nanoparticles><viruslike particle><µfluidic>